ES2672701T3 - Nuevos inhibidores de histona deacetilasa y su uso en terapia - Google Patents
Nuevos inhibidores de histona deacetilasa y su uso en terapia Download PDFInfo
- Publication number
- ES2672701T3 ES2672701T3 ES13792060.9T ES13792060T ES2672701T3 ES 2672701 T3 ES2672701 T3 ES 2672701T3 ES 13792060 T ES13792060 T ES 13792060T ES 2672701 T3 ES2672701 T3 ES 2672701T3
- Authority
- ES
- Spain
- Prior art keywords
- amino
- mmol
- pyridin
- methyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003276 histone deacetylase inhibitor Substances 0.000 title claims description 24
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title claims description 7
- 238000002560 therapeutic procedure Methods 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 73
- 150000003839 salts Chemical class 0.000 claims abstract description 45
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract description 29
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims abstract description 23
- 125000003118 aryl group Chemical group 0.000 claims abstract description 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 22
- 125000005843 halogen group Chemical group 0.000 claims abstract description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 18
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 17
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims abstract description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 14
- 150000002367 halogens Chemical class 0.000 claims abstract description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims abstract description 12
- 125000004442 acylamino group Chemical group 0.000 claims abstract description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 12
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims abstract description 11
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 10
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 9
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims abstract description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 8
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 8
- 125000001424 substituent group Chemical group 0.000 claims abstract description 8
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 7
- 125000006697 (C1-C3) aminoalkyl group Chemical group 0.000 claims abstract description 6
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims abstract description 6
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims abstract description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 6
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910006069 SO3H Inorganic materials 0.000 claims abstract description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims abstract description 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims abstract description 6
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 6
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims abstract description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims abstract description 5
- 125000004429 atom Chemical group 0.000 claims abstract description 5
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 5
- 239000011701 zinc Substances 0.000 claims abstract description 5
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 4
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 4
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims abstract description 3
- -1 C1-C3 alkyl aminosulfon Chemical compound 0.000 claims description 61
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 19
- 102000003964 Histone deacetylase Human genes 0.000 claims description 14
- 108090000353 Histone deacetylase Proteins 0.000 claims description 14
- 230000001684 chronic effect Effects 0.000 claims description 11
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- 230000004968 inflammatory condition Effects 0.000 claims description 7
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 6
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 6
- 208000006029 Cardiomegaly Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 206010027406 Mesothelioma Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 208000015114 central nervous system disease Diseases 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 206010000496 acne Diseases 0.000 claims description 5
- 229940034982 antineoplastic agent Drugs 0.000 claims description 5
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 5
- 208000007056 sickle cell anemia Diseases 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000002903 Thalassemia Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 208000034737 hemoglobinopathy Diseases 0.000 claims description 4
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- ZMBHJBSAUSFPSX-UHFFFAOYSA-N 7-[(5-fluoropyridin-2-yl)-(1-methylbenzimidazol-2-yl)amino]-n-hydroxyheptanamide Chemical compound N=1C2=CC=CC=C2N(C)C=1N(CCCCCCC(=O)NO)C1=CC=C(F)C=N1 ZMBHJBSAUSFPSX-UHFFFAOYSA-N 0.000 claims description 3
- DTSWVZIEMROXHQ-UHFFFAOYSA-N 7-[(5-fluoropyridin-2-yl)-(1-methylpyrazol-3-yl)amino]-n-hydroxyheptanamide Chemical compound CN1C=CC(N(CCCCCCC(=O)NO)C=2N=CC(F)=CC=2)=N1 DTSWVZIEMROXHQ-UHFFFAOYSA-N 0.000 claims description 3
- RUGSZKOQAROHTP-UHFFFAOYSA-N 7-[(5-fluoropyridin-2-yl)-(3-methyl-1,2,4-thiadiazol-5-yl)amino]-n-hydroxyheptanamide Chemical compound CC1=NSC(N(CCCCCCC(=O)NO)C=2N=CC(F)=CC=2)=N1 RUGSZKOQAROHTP-UHFFFAOYSA-N 0.000 claims description 3
- FCQMZQPBVGDJRA-UHFFFAOYSA-N 7-[(5-fluoropyridin-2-yl)-[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]amino]-n-hydroxyheptanamide Chemical compound C=1C=C(F)C=NC=1N(CCCCCCC(=O)NO)C1=NC(C(F)(F)F)=NS1 FCQMZQPBVGDJRA-UHFFFAOYSA-N 0.000 claims description 3
- SDHCJCKTSOINRV-UHFFFAOYSA-N 7-[1,3-benzoxazol-2-yl(pyridin-2-yl)amino]-n-hydroxyheptanamide Chemical compound N=1C2=CC=CC=C2OC=1N(CCCCCCC(=O)NO)C1=CC=CC=N1 SDHCJCKTSOINRV-UHFFFAOYSA-N 0.000 claims description 3
- XZLSRIUXMLZDIG-UHFFFAOYSA-N 7-[1,3-benzoxazol-2-yl-(5-fluoropyridin-2-yl)amino]-n-hydroxyheptanamide Chemical compound N=1C2=CC=CC=C2OC=1N(CCCCCCC(=O)NO)C1=CC=C(F)C=N1 XZLSRIUXMLZDIG-UHFFFAOYSA-N 0.000 claims description 3
- LYKCBCSSOCTSJS-UHFFFAOYSA-N 8-[1,3-benzoxazol-2-yl(pyridin-2-yl)amino]-n-hydroxyoctanamide Chemical compound N=1C2=CC=CC=C2OC=1N(CCCCCCCC(=O)NO)C1=CC=CC=N1 LYKCBCSSOCTSJS-UHFFFAOYSA-N 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 3
- 201000009273 Endometriosis Diseases 0.000 claims description 3
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 3
- 208000004179 Oral Leukoplakia Diseases 0.000 claims description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 3
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 210000002216 heart Anatomy 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- NHMTXYCRARFQSW-UHFFFAOYSA-N n-hydroxy-7-[(3-methyl-1,2,4-oxadiazol-5-yl)-pyridin-2-ylamino]heptanamide Chemical compound CC1=NOC(N(CCCCCCC(=O)NO)C=2N=CC=CC=2)=N1 NHMTXYCRARFQSW-UHFFFAOYSA-N 0.000 claims description 3
- JATJXQVARVZNCX-UHFFFAOYSA-N n-hydroxy-7-[pyridin-2-yl(1,2,4-thiadiazol-5-yl)amino]heptanamide Chemical compound C=1C=CC=NC=1N(CCCCCCC(=O)NO)C1=NC=NS1 JATJXQVARVZNCX-UHFFFAOYSA-N 0.000 claims description 3
- NSWXYHYGBYWCCU-UHFFFAOYSA-N n-hydroxy-7-[pyridin-2-yl(1,3-thiazol-2-yl)amino]heptanamide Chemical compound C=1C=CC=NC=1N(CCCCCCC(=O)NO)C1=NC=CS1 NSWXYHYGBYWCCU-UHFFFAOYSA-N 0.000 claims description 3
- FJPDRDDLAWLIEY-UHFFFAOYSA-N n-hydroxy-8-[(3-methyl-1,2,4-oxadiazol-5-yl)-pyridin-2-ylamino]octanamide Chemical compound CC1=NOC(N(CCCCCCCC(=O)NO)C=2N=CC=CC=2)=N1 FJPDRDDLAWLIEY-UHFFFAOYSA-N 0.000 claims description 3
- PLXKEIWLYDAYRS-UHFFFAOYSA-N n-hydroxy-8-[pyridin-2-yl-[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]amino]octanamide Chemical compound C=1C=CC=NC=1N(CCCCCCCC(=O)NO)C1=NC(C(F)(F)F)=NS1 PLXKEIWLYDAYRS-UHFFFAOYSA-N 0.000 claims description 3
- 201000008557 oral mucosa leukoplakia Diseases 0.000 claims description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- SJHVTQMOCHVEGJ-UHFFFAOYSA-N 7-[(5-fluoropyridin-2-yl)-(3-methyl-1,2,4-oxadiazol-5-yl)amino]-n-hydroxyheptanamide Chemical compound CC1=NOC(N(CCCCCCC(=O)NO)C=2N=CC(F)=CC=2)=N1 SJHVTQMOCHVEGJ-UHFFFAOYSA-N 0.000 claims description 2
- DMKMUYIOEGFWFU-UHFFFAOYSA-N 7-[[4-(4-fluorophenyl)pyridin-2-yl]-(1-methylpyrazol-3-yl)amino]-n-hydroxyheptanamide Chemical compound CN1C=CC(N(CCCCCCC(=O)NO)C=2N=CC=C(C=2)C=2C=CC(F)=CC=2)=N1 DMKMUYIOEGFWFU-UHFFFAOYSA-N 0.000 claims description 2
- MXYWXAXWKPIWRS-UHFFFAOYSA-N 8-[(5-fluoropyridin-2-yl)-(1-methylbenzimidazol-2-yl)amino]-n-hydroxyoctanamide Chemical compound N=1C2=CC=CC=C2N(C)C=1N(CCCCCCCC(=O)NO)C1=CC=C(F)C=N1 MXYWXAXWKPIWRS-UHFFFAOYSA-N 0.000 claims description 2
- VVJMWYSXFPSSLA-UHFFFAOYSA-N 8-[(5-fluoropyridin-2-yl)-(1-methylpyrazol-3-yl)amino]-n-hydroxyoctanamide Chemical compound CN1C=CC(N(CCCCCCCC(=O)NO)C=2N=CC(F)=CC=2)=N1 VVJMWYSXFPSSLA-UHFFFAOYSA-N 0.000 claims description 2
- ARWCVPUGRMZQCN-UHFFFAOYSA-N 8-[(5-fluoropyridin-2-yl)-[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]amino]-n-hydroxyoctanamide Chemical compound C=1C=C(F)C=NC=1N(CCCCCCCC(=O)NO)C1=NC(C(F)(F)F)=NS1 ARWCVPUGRMZQCN-UHFFFAOYSA-N 0.000 claims description 2
- NVXCNYOSHXXPBK-UHFFFAOYSA-N 8-[1,3-benzothiazol-2-yl(pyridin-2-yl)amino]-n-hydroxyoctanamide Chemical compound N=1C2=CC=CC=C2SC=1N(CCCCCCCC(=O)NO)C1=CC=CC=N1 NVXCNYOSHXXPBK-UHFFFAOYSA-N 0.000 claims description 2
- RQQWIHAMWSPVSE-UHFFFAOYSA-N 8-[[4-(4-fluorophenyl)pyridin-2-yl]-(1-methylpyrazol-3-yl)amino]-n-hydroxyoctanamide Chemical compound CN1C=CC(N(CCCCCCCC(=O)NO)C=2N=CC=C(C=2)C=2C=CC(F)=CC=2)=N1 RQQWIHAMWSPVSE-UHFFFAOYSA-N 0.000 claims description 2
- 206010020880 Hypertrophy Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 210000003780 hair follicle Anatomy 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims description 2
- XDQGBWWSDVYFDM-UHFFFAOYSA-N n-hydroxy-7-[(1-methylbenzimidazol-2-yl)-pyridin-2-ylamino]heptanamide Chemical compound N=1C2=CC=CC=C2N(C)C=1N(CCCCCCC(=O)NO)C1=CC=CC=N1 XDQGBWWSDVYFDM-UHFFFAOYSA-N 0.000 claims description 2
- OMIWXFMPPYEWJD-UHFFFAOYSA-N n-hydroxy-7-[(3-methyl-1,2,4-thiadiazol-5-yl)-pyridin-2-ylamino]heptanamide Chemical compound CC1=NSC(N(CCCCCCC(=O)NO)C=2N=CC=CC=2)=N1 OMIWXFMPPYEWJD-UHFFFAOYSA-N 0.000 claims description 2
- VGERKUSAMORGOJ-UHFFFAOYSA-N n-hydroxy-7-[(3-methyl-1,2,4-thiadiazol-5-yl)-pyridin-3-ylamino]heptanamide Chemical compound CC1=NSC(N(CCCCCCC(=O)NO)C=2C=NC=CC=2)=N1 VGERKUSAMORGOJ-UHFFFAOYSA-N 0.000 claims description 2
- JSQCZJVMRDOTJY-UHFFFAOYSA-N n-hydroxy-7-[(5-methyl-1,3,4-thiadiazol-2-yl)-pyridin-2-ylamino]heptanamide Chemical compound S1C(C)=NN=C1N(CCCCCCC(=O)NO)C1=CC=CC=N1 JSQCZJVMRDOTJY-UHFFFAOYSA-N 0.000 claims description 2
- FMMOJMFSSWGTLE-UHFFFAOYSA-N n-hydroxy-7-[pyridin-2-yl(1,3,4-thiadiazol-2-yl)amino]heptanamide Chemical compound C=1C=CC=NC=1N(CCCCCCC(=O)NO)C1=NN=CS1 FMMOJMFSSWGTLE-UHFFFAOYSA-N 0.000 claims description 2
- CQDPQUJZWARWAJ-UHFFFAOYSA-N n-hydroxy-7-[pyridin-2-yl-[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]amino]heptanamide Chemical compound C=1C=CC=NC=1N(CCCCCCC(=O)NO)C1=NC(C(F)(F)F)=NS1 CQDPQUJZWARWAJ-UHFFFAOYSA-N 0.000 claims description 2
- WGULHDOTIUCDOF-UHFFFAOYSA-N n-hydroxy-8-[pyridin-2-yl(1,2,4-thiadiazol-5-yl)amino]octanamide Chemical compound C=1C=CC=NC=1N(CCCCCCCC(=O)NO)C1=NC=NS1 WGULHDOTIUCDOF-UHFFFAOYSA-N 0.000 claims description 2
- CUKKJLDAKAAXPV-UHFFFAOYSA-N n-hydroxy-8-[pyridin-2-yl(1,3,4-thiadiazol-2-yl)amino]octanamide Chemical compound C=1C=CC=NC=1N(CCCCCCCC(=O)NO)C1=NN=CS1 CUKKJLDAKAAXPV-UHFFFAOYSA-N 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 201000004990 juvenile ankylosing spondylitis Diseases 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- DJNFAOJJLHYPLD-UHFFFAOYSA-N 8-[(5-fluoropyridin-2-yl)-(3-methyl-1,2,4-oxadiazol-5-yl)amino]-n-hydroxyoctanamide Chemical compound CC1=NOC(N(CCCCCCCC(=O)NO)C=2N=CC(F)=CC=2)=N1 DJNFAOJJLHYPLD-UHFFFAOYSA-N 0.000 claims 1
- CGUBVAYZBHRVKC-UHFFFAOYSA-N 8-[(5-fluoropyridin-2-yl)-(3-methyl-1,2,4-thiadiazol-5-yl)amino]-n-hydroxyoctanamide Chemical compound CC1=NSC(N(CCCCCCCC(=O)NO)C=2N=CC(F)=CC=2)=N1 CGUBVAYZBHRVKC-UHFFFAOYSA-N 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- RNGALPYBZBJTTJ-UHFFFAOYSA-N n-hydroxy-7-[(1-methylpyrazol-3-yl)-pyridin-2-ylamino]heptanamide Chemical compound CN1C=CC(N(CCCCCCC(=O)NO)C=2N=CC=CC=2)=N1 RNGALPYBZBJTTJ-UHFFFAOYSA-N 0.000 claims 1
- OSINRMKTBBRGTB-UHFFFAOYSA-N n-hydroxy-8-[(1-methylbenzimidazol-2-yl)-pyridin-2-ylamino]octanamide Chemical compound N=1C2=CC=CC=C2N(C)C=1N(CCCCCCCC(=O)NO)C1=CC=CC=N1 OSINRMKTBBRGTB-UHFFFAOYSA-N 0.000 claims 1
- KLIXIZXCGNMXIL-UHFFFAOYSA-N n-hydroxy-8-[(1-methylpyrazol-3-yl)-pyridin-2-ylamino]octanamide Chemical compound CN1C=CC(N(CCCCCCCC(=O)NO)C=2N=CC=CC=2)=N1 KLIXIZXCGNMXIL-UHFFFAOYSA-N 0.000 claims 1
- ZZAVVVJBEKDJKC-UHFFFAOYSA-N n-hydroxy-8-[(5-methyl-1,3,4-thiadiazol-2-yl)-pyridin-2-ylamino]octanamide Chemical compound S1C(C)=NN=C1N(CCCCCCCC(=O)NO)C1=CC=CC=N1 ZZAVVVJBEKDJKC-UHFFFAOYSA-N 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 561
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 242
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 175
- 239000011541 reaction mixture Substances 0.000 description 164
- 235000019439 ethyl acetate Nutrition 0.000 description 121
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 114
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 98
- 239000012074 organic phase Substances 0.000 description 94
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 93
- 229910001868 water Inorganic materials 0.000 description 92
- 239000007787 solid Substances 0.000 description 89
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 88
- 238000003818 flash chromatography Methods 0.000 description 88
- 229910052938 sodium sulfate Inorganic materials 0.000 description 88
- 235000011152 sodium sulphate Nutrition 0.000 description 88
- 239000007832 Na2SO4 Substances 0.000 description 87
- 239000000243 solution Substances 0.000 description 47
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 46
- VIVUIVDQNJGPDT-UHFFFAOYSA-N n-[4-(4-fluorophenyl)pyridin-2-yl]-3-methyl-1,2,4-thiadiazol-5-amine Chemical compound CC1=NSC(NC=2N=CC=C(C=2)C=2C=CC(F)=CC=2)=N1 VIVUIVDQNJGPDT-UHFFFAOYSA-N 0.000 description 42
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 41
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 40
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 40
- 229910017912 NH2OH Inorganic materials 0.000 description 39
- 238000005160 1H NMR spectroscopy Methods 0.000 description 38
- 239000012267 brine Substances 0.000 description 38
- 239000000706 filtrate Substances 0.000 description 36
- 239000000203 mixture Substances 0.000 description 35
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 34
- KAHBUJXIACKEFX-UHFFFAOYSA-N ethyl 7-[[4-(4-fluorophenyl)pyridin-2-yl]-(3-methyl-1,2,4-thiadiazol-5-yl)amino]heptanoate Chemical compound C=1C(C=2C=CC(F)=CC=2)=CC=NC=1N(CCCCCCC(=O)OCC)C1=NC(C)=NS1 KAHBUJXIACKEFX-UHFFFAOYSA-N 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 201000010099 disease Diseases 0.000 description 24
- LIGSYCKWSWDUKG-UHFFFAOYSA-N 2-chloro-4-(4-fluorophenyl)pyridine Chemical compound C1=CC(F)=CC=C1C1=CC=NC(Cl)=C1 LIGSYCKWSWDUKG-UHFFFAOYSA-N 0.000 description 23
- YYZUSRORWSJGET-UHFFFAOYSA-N ethyl octanoate Chemical compound CCCCCCCC(=O)OCC YYZUSRORWSJGET-UHFFFAOYSA-N 0.000 description 23
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 22
- MCZJFFUPCJJZSD-UHFFFAOYSA-N 5-chloro-3-(trifluoromethyl)-1,2,4-thiadiazole Chemical compound FC(F)(F)C1=NSC(Cl)=N1 MCZJFFUPCJJZSD-UHFFFAOYSA-N 0.000 description 21
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 20
- VMIBXGDYRRTQMO-UHFFFAOYSA-N ethyl 7-iodoheptanoate Chemical compound CCOC(=O)CCCCCCI VMIBXGDYRRTQMO-UHFFFAOYSA-N 0.000 description 20
- TVQGDYNRXLTQAP-UHFFFAOYSA-N ethyl heptanoate Chemical compound CCCCCCC(=O)OCC TVQGDYNRXLTQAP-UHFFFAOYSA-N 0.000 description 20
- HYNNFHYYEVPUMG-UHFFFAOYSA-N ethyl 8-iodooctanoate Chemical compound CCOC(=O)CCCCCCCI HYNNFHYYEVPUMG-UHFFFAOYSA-N 0.000 description 19
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 230000033115 angiogenesis Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 229910000024 caesium carbonate Inorganic materials 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 208000037976 chronic inflammation Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 206010018691 Granuloma Diseases 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 235000019253 formic acid Nutrition 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- PUSKHXMZPOMNTQ-UHFFFAOYSA-N ethyl 2,1,3-benzoselenadiazole-5-carboxylate Chemical compound CCOC(=O)C1=CC=C2N=[Se]=NC2=C1 PUSKHXMZPOMNTQ-UHFFFAOYSA-N 0.000 description 5
- AEDIXYWIVPYNBI-UHFFFAOYSA-N heptanamide Chemical compound CCCCCCC(N)=O AEDIXYWIVPYNBI-UHFFFAOYSA-N 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- MOGQNVSKBCVIPW-UHFFFAOYSA-N 1-methylpyrazol-3-amine Chemical compound CN1C=CC(N)=N1 MOGQNVSKBCVIPW-UHFFFAOYSA-N 0.000 description 4
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 4
- UODINHBLNPPDPD-UHFFFAOYSA-N 2-bromo-5-fluoropyridine Chemical compound FC1=CC=C(Br)N=C1 UODINHBLNPPDPD-UHFFFAOYSA-N 0.000 description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 4
- ILTLLMVRPBXCSX-UHFFFAOYSA-N 5-chloro-3-methyl-1,2,4-thiadiazole Chemical compound CC1=NSC(Cl)=N1 ILTLLMVRPBXCSX-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 4
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 4
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000002491 angiogenic effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000006020 chronic inflammation Effects 0.000 description 4
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 4
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 206010023332 keratitis Diseases 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- XFLJTZVMJDWKPC-UHFFFAOYSA-N n-(5-fluoropyridin-2-yl)-3-methyl-1,2,4-thiadiazol-5-amine Chemical compound CC1=NSC(NC=2N=CC(F)=CC=2)=N1 XFLJTZVMJDWKPC-UHFFFAOYSA-N 0.000 description 4
- LTHCSWBWNVGEFE-UHFFFAOYSA-N octanamide Chemical compound CCCCCCCC(N)=O LTHCSWBWNVGEFE-UHFFFAOYSA-N 0.000 description 4
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 4
- 230000009696 proliferative response Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 201000000306 sarcoidosis Diseases 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 125000004516 1,2,4-thiadiazol-5-yl group Chemical group S1N=CN=C1* 0.000 description 3
- IMSYJURZIBEMAF-UHFFFAOYSA-N 3-methyl-n-pyridin-2-yl-1,2,4-oxadiazol-5-amine Chemical compound CC1=NOC(NC=2N=CC=CC=2)=N1 IMSYJURZIBEMAF-UHFFFAOYSA-N 0.000 description 3
- REIRFEWEBLNCRE-UHFFFAOYSA-N 5-fluoro-n-(1-methylpyrazol-3-yl)pyridin-2-amine Chemical compound CN1C=CC(NC=2N=CC(F)=CC=2)=N1 REIRFEWEBLNCRE-UHFFFAOYSA-N 0.000 description 3
- YJTXQLYMECWULH-UHFFFAOYSA-N 5-fluoropyridin-2-amine Chemical compound NC1=CC=C(F)C=N1 YJTXQLYMECWULH-UHFFFAOYSA-N 0.000 description 3
- WGNIDGKMVZETEV-UHFFFAOYSA-N 5-methyl-n-pyridin-2-yl-1,3,4-thiadiazol-2-amine Chemical compound S1C(C)=NN=C1NC1=CC=CC=N1 WGNIDGKMVZETEV-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- GKSNDWBVEGIBSB-UHFFFAOYSA-N n-(1-methylpyrazol-3-yl)pyridin-2-amine Chemical compound CN1C=CC(NC=2N=CC=CC=2)=N1 GKSNDWBVEGIBSB-UHFFFAOYSA-N 0.000 description 3
- FFCGYTKCHGGJKV-UHFFFAOYSA-N n-(5-fluoropyridin-2-yl)-1,3-benzoxazol-2-amine Chemical compound N1=CC(F)=CC=C1NC1=NC2=CC=CC=C2O1 FFCGYTKCHGGJKV-UHFFFAOYSA-N 0.000 description 3
- TUJPAACKAWOMQX-UHFFFAOYSA-N n-(5-fluoropyridin-2-yl)-1-methylbenzimidazol-2-amine Chemical compound N=1C2=CC=CC=C2N(C)C=1NC1=CC=C(F)C=N1 TUJPAACKAWOMQX-UHFFFAOYSA-N 0.000 description 3
- ANHYKLVQPLIQDE-UHFFFAOYSA-N n-(5-fluoropyridin-2-yl)-3-(trifluoromethyl)-1,2,4-thiadiazol-5-amine Chemical compound N1=CC(F)=CC=C1NC1=NC(C(F)(F)F)=NS1 ANHYKLVQPLIQDE-UHFFFAOYSA-N 0.000 description 3
- ZNKBUWSOACZPMJ-UHFFFAOYSA-N n-(5-fluoropyridin-2-yl)-3-methyl-1,2,4-oxadiazol-5-amine Chemical compound CC1=NOC(NC=2N=CC(F)=CC=2)=N1 ZNKBUWSOACZPMJ-UHFFFAOYSA-N 0.000 description 3
- DIOSBEIABPQMLZ-UHFFFAOYSA-N n-pyridin-2-yl-1,3-benzothiazol-2-amine Chemical compound N=1C2=CC=CC=C2SC=1NC1=CC=CC=N1 DIOSBEIABPQMLZ-UHFFFAOYSA-N 0.000 description 3
- YMRWEBLZMFGRTH-UHFFFAOYSA-N n-pyridin-2-yl-1,3-benzoxazol-2-amine Chemical compound N=1C2=CC=CC=C2OC=1NC1=CC=CC=N1 YMRWEBLZMFGRTH-UHFFFAOYSA-N 0.000 description 3
- GYVUGWTVTJMFLI-UHFFFAOYSA-N n-pyridin-2-yl-1,3-thiazol-2-amine Chemical compound C=1C=CC=NC=1NC1=NC=CS1 GYVUGWTVTJMFLI-UHFFFAOYSA-N 0.000 description 3
- UBBVFEHMJRIGIY-UHFFFAOYSA-N n-pyridin-2-yl-3-(trifluoromethyl)-1,2,4-thiadiazol-5-amine Chemical compound FC(F)(F)C1=NSC(NC=2N=CC=CC=2)=N1 UBBVFEHMJRIGIY-UHFFFAOYSA-N 0.000 description 3
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- VJHTZTZXOKVQRN-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine Chemical compound NC1=NC=NS1 VJHTZTZXOKVQRN-UHFFFAOYSA-N 0.000 description 2
- JPBLHOJFMBOCAF-UHFFFAOYSA-N 1,3-benzoxazol-2-amine Chemical compound C1=CC=C2OC(N)=NC2=C1 JPBLHOJFMBOCAF-UHFFFAOYSA-N 0.000 description 2
- LRDRIWQGCVIEQI-UHFFFAOYSA-N 1-methyl-n-pyridin-2-ylbenzimidazol-2-amine Chemical compound N=1C2=CC=CC=C2N(C)C=1NC1=CC=CC=N1 LRDRIWQGCVIEQI-UHFFFAOYSA-N 0.000 description 2
- XDFZKQJLNGNJAN-UHFFFAOYSA-N 1-methylbenzimidazol-2-amine Chemical compound C1=CC=C2N(C)C(N)=NC2=C1 XDFZKQJLNGNJAN-UHFFFAOYSA-N 0.000 description 2
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 2
- UASBPOOBTIHEPT-UHFFFAOYSA-N 2-hydroxyheptanamide Chemical compound CCCCCC(O)C(N)=O UASBPOOBTIHEPT-UHFFFAOYSA-N 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- LGNNZKURGCOEJY-UHFFFAOYSA-N 3-methyl-1,2,4-oxadiazol-5-amine Chemical compound CC1=NOC(N)=N1 LGNNZKURGCOEJY-UHFFFAOYSA-N 0.000 description 2
- NZQMQRRJBGZTCU-UHFFFAOYSA-N 7-[1,3-benzothiazol-2-yl(pyridin-2-yl)amino]-n-hydroxyheptanamide Chemical compound N=1C2=CC=CC=C2SC=1N(CCCCCCC(=O)NO)C1=CC=CC=N1 NZQMQRRJBGZTCU-UHFFFAOYSA-N 0.000 description 2
- AZYMNAHHBIKAIP-UHFFFAOYSA-N 8-[[4-(4-fluorophenyl)pyridin-2-yl]-(3-methyl-1,2,4-thiadiazol-5-yl)amino]-n-hydroxyoctanamide Chemical compound CC1=NSC(N(CCCCCCCC(=O)NO)C=2N=CC=C(C=2)C=2C=CC(F)=CC=2)=N1 AZYMNAHHBIKAIP-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
- 206010011017 Corneal graft rejection Diseases 0.000 description 2
- 206010055665 Corneal neovascularisation Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 2
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 2
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 2
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- 206010062207 Mycobacterial infection Diseases 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 206010037075 Protozoal infections Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 201000000159 corneal neovascularization Diseases 0.000 description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- ATKLZFAKVSVLOJ-UHFFFAOYSA-N ethyl 7-[1,3-benzoxazol-2-yl(pyridin-2-yl)amino]heptanoate Chemical compound N=1C2=CC=CC=C2OC=1N(CCCCCCC(=O)OCC)C1=CC=CC=N1 ATKLZFAKVSVLOJ-UHFFFAOYSA-N 0.000 description 2
- MUHFLFPYYKZSOW-UHFFFAOYSA-N ethyl 7-[pyridin-2-yl(1,2,4-thiadiazol-5-yl)amino]heptanoate Chemical compound C=1C=CC=NC=1N(CCCCCCC(=O)OCC)C1=NC=NS1 MUHFLFPYYKZSOW-UHFFFAOYSA-N 0.000 description 2
- MDMOGIHLWKAXHF-UHFFFAOYSA-N ethyl 7-[pyridin-2-yl(1,3,4-thiadiazol-2-yl)amino]heptanoate Chemical compound C=1C=CC=NC=1N(CCCCCCC(=O)OCC)C1=NN=CS1 MDMOGIHLWKAXHF-UHFFFAOYSA-N 0.000 description 2
- LVCIKBSGTAZCLL-UHFFFAOYSA-N ethyl 8-[1,3-benzoxazol-2-yl(pyridin-2-yl)amino]octanoate Chemical compound N=1C2=CC=CC=C2OC=1N(CCCCCCCC(=O)OCC)C1=CC=CC=N1 LVCIKBSGTAZCLL-UHFFFAOYSA-N 0.000 description 2
- HKJUTWXEMUDGGY-UHFFFAOYSA-N ethyl 8-[pyridin-2-yl(1,2,4-thiadiazol-5-yl)amino]octanoate Chemical compound C=1C=CC=NC=1N(CCCCCCCC(=O)OCC)C1=NC=NS1 HKJUTWXEMUDGGY-UHFFFAOYSA-N 0.000 description 2
- HSQDDAALAQZISF-UHFFFAOYSA-N ethyl 8-[pyridin-2-yl(1,3,4-thiadiazol-2-yl)amino]octanoate Chemical compound C=1C=CC=NC=1N(CCCCCCCC(=O)OCC)C1=NN=CS1 HSQDDAALAQZISF-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- YPJRHEKCFKOVRT-UHFFFAOYSA-N lerociclib Chemical compound C1CN(C(C)C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C2N3C4(CCCCC4)CNC2=O)C3=N1 YPJRHEKCFKOVRT-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- YXEYORBCTRRZNC-UHFFFAOYSA-N n-pyridin-2-yl-1,2,4-thiadiazol-5-amine Chemical compound C=1C=CC=NC=1NC1=NC=NS1 YXEYORBCTRRZNC-UHFFFAOYSA-N 0.000 description 2
- 201000003142 neovascular glaucoma Diseases 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 150000003057 platinum Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- OMGHIGVFLOPEHJ-BYPYZUCNSA-N (2s)-2,5-dihydro-1h-pyrrole-2-carboxylic acid Chemical compound OC(=O)[C@H]1NCC=C1 OMGHIGVFLOPEHJ-BYPYZUCNSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- QUKGLNCXGVWCJX-UHFFFAOYSA-N 1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=CS1 QUKGLNCXGVWCJX-UHFFFAOYSA-N 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- LSEFXLGTUCVBPE-UHFFFAOYSA-N 1h-imidazol-2-ylcarbamic acid Chemical compound OC(=O)NC1=NC=CN1 LSEFXLGTUCVBPE-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- UHGULLIUJBCTEF-UHFFFAOYSA-N 2-aminobenzothiazole Chemical compound C1=CC=C2SC(N)=NC2=C1 UHGULLIUJBCTEF-UHFFFAOYSA-N 0.000 description 1
- NYPGBHKJFKQTIY-TYYBGVCCSA-N 2-cyanoethylazanium;(e)-4-hydroxy-4-oxobut-2-enoate Chemical compound NCCC#N.OC(=O)\C=C\C(O)=O NYPGBHKJFKQTIY-TYYBGVCCSA-N 0.000 description 1
- SLQVRRTZDSTHAC-UHFFFAOYSA-N 2-hydroxyoctanamide Chemical compound CCCCCCC(O)C(N)=O SLQVRRTZDSTHAC-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- DJKUIGPCSNRFRK-UHFFFAOYSA-N 3-methyl-1,2,4-thiadiazol-5-amine Chemical compound CC1=NSC(N)=N1 DJKUIGPCSNRFRK-UHFFFAOYSA-N 0.000 description 1
- MWXPGVONCSFURJ-UHFFFAOYSA-N 3-methyl-n-pyridin-2-yl-1,2,4-thiadiazol-5-amine Chemical compound CC1=NSC(NC=2N=CC=CC=2)=N1 MWXPGVONCSFURJ-UHFFFAOYSA-N 0.000 description 1
- ZPWWCQYOFQXVNE-UHFFFAOYSA-N 3-methyl-n-pyridin-3-yl-1,2,4-thiadiazol-5-amine Chemical compound CC1=NSC(NC=2C=NC=CC=2)=N1 ZPWWCQYOFQXVNE-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BOCATKBAKISRLA-UHFFFAOYSA-N 4-propyl-5-pyridin-4-yl-3h-1,3-oxazol-2-one Chemical compound N1C(=O)OC(C=2C=CN=CC=2)=C1CCC BOCATKBAKISRLA-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- HMPUHXCGUHDVBI-UHFFFAOYSA-N 5-methyl-1,3,4-thiadiazol-2-amine Chemical compound CC1=NN=C(N)S1 HMPUHXCGUHDVBI-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- QCRYHEUPFNGKNB-UHFFFAOYSA-N 7-[[4-(4-fluorophenyl)pyridin-2-yl]-(3-methyl-1,2,4-thiadiazol-5-yl)amino]-n-hydroxyheptanamide Chemical compound CC1=NSC(N(CCCCCCC(=O)NO)C=2N=CC=C(C=2)C=2C=CC(F)=CC=2)=N1 QCRYHEUPFNGKNB-UHFFFAOYSA-N 0.000 description 1
- FQNMAWUQAQHBRY-UHFFFAOYSA-N 8-[1,3-benzoxazol-2-yl-(5-fluoropyridin-2-yl)amino]-n-hydroxyoctanamide Chemical compound N=1C2=CC=CC=C2OC=1N(CCCCCCCC(=O)NO)C1=CC=C(F)C=N1 FQNMAWUQAQHBRY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 102000012936 Angiostatins Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000003609 Bile Duct Adenoma Diseases 0.000 description 1
- 206010048798 Biliary adenoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000003163 Cavernous Hemangioma Diseases 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 206010061809 Cervix carcinoma stage 0 Diseases 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 108010040512 Clupeine Proteins 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 241000223936 Cryptosporidium parvum Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000304695 Eimeria sp. Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- ZPLVYYNMRMBNGE-UHFFFAOYSA-N Eponemycin Natural products CC(C)CCCCC(=O)NC(CO)C(=O)NC(CC(C)=C)C(=O)C1(CO)CO1 ZPLVYYNMRMBNGE-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000004057 Focal Nodular Hyperplasia Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019629 Hepatic adenoma Diseases 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010051151 Hyperviscosity syndrome Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010025412 Macular dystrophy congenital Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000024599 Mooren ulcer Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010051081 Nodular regenerative hyperplasia Diseases 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000004788 Pars Planitis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037649 Pyogenic granuloma Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000146987 Sarcocystis neurona Species 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000018656 Terrien marginal degeneration Diseases 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010058990 Venous occlusion Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 206010047663 Vitritis Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 150000005325 alkali earth metal hydroxides Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 description 1
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000000964 angiostatic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000011230 antibody-based therapy Methods 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- AMHIJMKZPBMCKI-PKLGAXGESA-N ctds Chemical compound O[C@@H]1[C@@H](OS(O)(=O)=O)[C@@H]2O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@H](CO)[C@H]1O[C@@H](O[C@@H]1CO)[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H]1O[C@@H](O[C@@H]1CO)[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H]1O[C@@H](O[C@@H]1CO)[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H]1O[C@@H](O[C@@H]1CO)[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H]1O[C@@H](O[C@@H]1CO)[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H]1O2 AMHIJMKZPBMCKI-PKLGAXGESA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- ZPLVYYNMRMBNGE-TWOQFEAHSA-N eponemycin Chemical compound CC(C)CCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)=C)C(=O)[C@@]1(CO)CO1 ZPLVYYNMRMBNGE-TWOQFEAHSA-N 0.000 description 1
- DTHXWMOXBRBHTR-UHFFFAOYSA-N ethyl 7-[(1-methylbenzimidazol-2-yl)-pyridin-2-ylamino]heptanoate Chemical compound N=1C2=CC=CC=C2N(C)C=1N(CCCCCCC(=O)OCC)C1=CC=CC=N1 DTHXWMOXBRBHTR-UHFFFAOYSA-N 0.000 description 1
- MZZAHXGFUIPCLI-UHFFFAOYSA-N ethyl 7-[(3-methyl-1,2,4-thiadiazol-5-yl)-pyridin-2-ylamino]heptanoate Chemical compound C=1C=CC=NC=1N(CCCCCCC(=O)OCC)C1=NC(C)=NS1 MZZAHXGFUIPCLI-UHFFFAOYSA-N 0.000 description 1
- ZXAZRDHCIHOWCY-UHFFFAOYSA-N ethyl 7-[(5-fluoropyridin-2-yl)-(1-methylbenzimidazol-2-yl)amino]heptanoate Chemical compound N=1C2=CC=CC=C2N(C)C=1N(CCCCCCC(=O)OCC)C1=CC=C(F)C=N1 ZXAZRDHCIHOWCY-UHFFFAOYSA-N 0.000 description 1
- WRUVUUZOGBHUIK-UHFFFAOYSA-N ethyl 7-[(5-fluoropyridin-2-yl)-(3-methyl-1,2,4-oxadiazol-5-yl)amino]heptanoate Chemical compound C=1C=C(F)C=NC=1N(CCCCCCC(=O)OCC)C1=NC(C)=NO1 WRUVUUZOGBHUIK-UHFFFAOYSA-N 0.000 description 1
- ANDBESOFCWPDRG-UHFFFAOYSA-N ethyl 7-[(5-fluoropyridin-2-yl)-(3-methyl-1,2,4-thiadiazol-5-yl)amino]heptanoate Chemical compound C=1C=C(F)C=NC=1N(CCCCCCC(=O)OCC)C1=NC(C)=NS1 ANDBESOFCWPDRG-UHFFFAOYSA-N 0.000 description 1
- PREPSOUWLBPYLM-UHFFFAOYSA-N ethyl 7-[pyridin-2-yl-[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]amino]heptanoate Chemical compound C=1C=CC=NC=1N(CCCCCCC(=O)OCC)C1=NC(C(F)(F)F)=NS1 PREPSOUWLBPYLM-UHFFFAOYSA-N 0.000 description 1
- OOBFNDGMAGSNKA-UHFFFAOYSA-N ethyl 7-bromoheptanoate Chemical compound CCOC(=O)CCCCCCBr OOBFNDGMAGSNKA-UHFFFAOYSA-N 0.000 description 1
- TXSIBVWHCXSHCS-UHFFFAOYSA-N ethyl 8-[(5-fluoropyridin-2-yl)-(3-methyl-1,2,4-oxadiazol-5-yl)amino]octanoate Chemical compound C=1C=C(F)C=NC=1N(CCCCCCCC(=O)OCC)C1=NC(C)=NO1 TXSIBVWHCXSHCS-UHFFFAOYSA-N 0.000 description 1
- YASGNZQRIABMCB-UHFFFAOYSA-N ethyl 8-[(5-fluoropyridin-2-yl)-(3-methyl-1,2,4-thiadiazol-5-yl)amino]octanoate Chemical compound C=1C=C(F)C=NC=1N(CCCCCCCC(=O)OCC)C1=NC(C)=NS1 YASGNZQRIABMCB-UHFFFAOYSA-N 0.000 description 1
- BHVVFCVMGAICJQ-UHFFFAOYSA-N ethyl 8-[[4-(4-fluorophenyl)pyridin-2-yl]-(3-methyl-1,2,4-thiadiazol-5-yl)amino]octanoate Chemical compound C=1C(C=2C=CC(F)=CC=2)=CC=NC=1N(CCCCCCCC(=O)OCC)C1=NC(C)=NS1 BHVVFCVMGAICJQ-UHFFFAOYSA-N 0.000 description 1
- SBJLNUBIWSEOQH-UHFFFAOYSA-N ethyl 8-[pyridin-2-yl-[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]amino]octanoate Chemical compound C=1C=CC=NC=1N(CCCCCCCC(=O)OCC)C1=NC(C(F)(F)F)=NS1 SBJLNUBIWSEOQH-UHFFFAOYSA-N 0.000 description 1
- UBTQVPMVWAEGAC-UHFFFAOYSA-N ethyl 8-bromooctanoate Chemical compound CCOC(=O)CCCCCCCBr UBTQVPMVWAEGAC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005219 extrinsic cardiomyopathy Diseases 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 230000002344 fibroplastic effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000001497 fibrovascular Effects 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 229940084434 fungoid Drugs 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940015045 gold sodium thiomalate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000010758 granulomatous inflammation Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 201000002735 hepatocellular adenoma Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 208000013653 hyalitis Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 201000007170 intrinsic cardiomyopathy Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 230000035984 keratolysis Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- UGDPYGKWIHHBMB-UHFFFAOYSA-N lobenzarit Chemical compound OC(=O)C1=CC=CC=C1NC1=CC(Cl)=CC=C1C(O)=O UGDPYGKWIHHBMB-UHFFFAOYSA-N 0.000 description 1
- 229950005662 lobenzarit Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- JLQSORLUJDAKHZ-UHFFFAOYSA-N n-pyridin-2-yl-1,3,4-thiadiazol-2-amine Chemical compound C=1C=CC=NC=1NC1=NN=CS1 JLQSORLUJDAKHZ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000021278 peroxisomal biogenesis disease Diseases 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000030266 primary brain neoplasm Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229950001139 timonacic Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1220029.1A GB201220029D0 (en) | 2012-11-07 | 2012-11-07 | Compounds |
| GB201220029 | 2012-11-07 | ||
| GB201309015 | 2013-05-20 | ||
| GB201309015A GB201309015D0 (en) | 2013-05-20 | 2013-05-20 | Compounds |
| GB201315254 | 2013-08-28 | ||
| GB201315254A GB201315254D0 (en) | 2013-08-28 | 2013-08-28 | Compounds |
| PCT/GB2013/052917 WO2014072714A1 (en) | 2012-11-07 | 2013-11-06 | Novel histone deacetylase inhibitors and their use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2672701T3 true ES2672701T3 (es) | 2018-06-15 |
Family
ID=49585430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13792060.9T Active ES2672701T3 (es) | 2012-11-07 | 2013-11-06 | Nuevos inhibidores de histona deacetilasa y su uso en terapia |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9676765B2 (online.php) |
| EP (1) | EP2917202B1 (online.php) |
| JP (1) | JP6329958B2 (online.php) |
| CN (1) | CN104797573A (online.php) |
| AU (1) | AU2013343291B2 (online.php) |
| CA (1) | CA2888861A1 (online.php) |
| ES (1) | ES2672701T3 (online.php) |
| IN (1) | IN2015DN03235A (online.php) |
| MX (1) | MX364295B (online.php) |
| NZ (1) | NZ707366A (online.php) |
| WO (1) | WO2014072714A1 (online.php) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105669540A (zh) | 2009-01-28 | 2016-06-15 | 卡鲁斯治疗有限公司 | Scriptaid电子等排体及其在治疗中的用途 |
| IN2015DN03235A (online.php) | 2012-11-07 | 2015-10-02 | Karus Therapeutics Ltd | |
| ES2688815T3 (es) | 2013-05-10 | 2018-11-07 | Karus Therapeutics Limited | Inhibidores de histona desacetilasa novedosos |
| KR102567244B1 (ko) * | 2014-06-12 | 2023-08-16 | 세다르스-신나이 메디칼 센터 | 암을 치료하는 조성물 및 방법 |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419228D0 (en) * | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| EP3737376B1 (en) * | 2018-01-09 | 2024-04-17 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human diseases |
| BR112021026334A2 (pt) | 2019-06-27 | 2022-05-10 | Medstar Health | Macrófagos ativados por hdac6, composições, e usos dos mesmos |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| US4792562A (en) | 1985-12-04 | 1988-12-20 | Hoechst-Roussel Pharmaceuticals, Inc. | N-(pyrrol-1-yl)pyridinamines having memory enhancing activity |
| JPH0532662A (ja) | 1990-11-09 | 1993-02-09 | Nissan Chem Ind Ltd | 置換ピラゾール誘導体および農園芸用殺菌剤 |
| US5214038A (en) * | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| JP2000511883A (ja) | 1996-04-19 | 2000-09-12 | ノボ ノルディスク アクティーゼルスカブ | ホスホチロシン認識ユニットを有する分子のモジュレーター |
| EP0887348A1 (en) | 1997-06-25 | 1998-12-30 | Boehringer Mannheim Italia S.p.A. | Bis-Indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them |
| JP3712529B2 (ja) | 1998-04-24 | 2005-11-02 | 大鵬薬品工業株式会社 | ３，３−ジピリジルアクリル酸アミド誘導体又はその薬学的に許容される塩 |
| HK1043840B (zh) | 1999-02-12 | 2005-05-20 | Hoya株式会社 | 眼镜镜片的制造方法 |
| JP5278983B2 (ja) | 1999-11-17 | 2013-09-04 | 塩野義製薬株式会社 | アミド化合物の新規用途 |
| GB9929988D0 (en) | 1999-12-17 | 2000-02-09 | Celltech Therapeutics Ltd | Chemical compounds |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| AU5261001A (en) | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
| US6635640B2 (en) | 2000-06-30 | 2003-10-21 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| JP2002255964A (ja) * | 2000-10-24 | 2002-09-11 | Sankyo Co Ltd | イミダゾピリジン誘導体 |
| AU2001295992A1 (en) * | 2000-10-24 | 2002-05-06 | Sankyo Company Limited | Imidazopyridine derivatives |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| US7429593B2 (en) | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
| AU2003218737B2 (en) | 2002-03-13 | 2008-04-10 | Janssen Pharmaceutica N.V. | Inhibitors of histone deacetylase |
| JP2003313126A (ja) * | 2002-04-23 | 2003-11-06 | Sankyo Co Ltd | イミダゾピリジン誘導体を有効成分とする医薬 |
| JP2004002826A (ja) * | 2002-04-24 | 2004-01-08 | Sankyo Co Ltd | 高分子イミダゾピリジン誘導体 |
| JP4235726B2 (ja) * | 2002-11-19 | 2009-03-11 | 国立大学法人 奈良先端科学技術大学院大学 | 大きな二光子吸収特性を示すアセチレン結合により連結されたビス（イミダゾリルポルフィリン金属錯体）を構成単位とするポルフィリン連鎖体及びその製造方法 |
| AU2003900608A0 (en) | 2003-02-11 | 2003-02-27 | Fujisawa Pharmaceutical Co., Ltd. | Hdac inhibitor |
| WO2005082887A1 (ja) | 2004-02-26 | 2005-09-09 | Aska Pharmaceutical Co., Ltd. | ピリミジン誘導体 |
| BRPI0511722A (pt) | 2004-06-01 | 2008-01-08 | Hoffmann La Roche | 3-amino-1-arilpropilindóis como inibidores da recaptação de monoamina |
| EP1809381A2 (en) | 2004-10-06 | 2007-07-25 | Recepticon ApS | Use of compounds for the prevention of drug-induced cell toxicity |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| CA2596015A1 (en) | 2005-02-14 | 2006-08-24 | Sampath K. Anandan | Fused heterocyclic compounds useful as inhibitors of histone deacetylase |
| KR20080016659A (ko) | 2005-05-20 | 2008-02-21 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제의 억제제로서 유용한 피롤로피리딘 |
| TW200716545A (en) * | 2005-06-10 | 2007-05-01 | Sigma Tau Ind Farmaceuti | Indole derivatives having anti-tumor activity |
| US8148535B2 (en) | 2005-10-21 | 2012-04-03 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| JP2009523812A (ja) | 2006-01-19 | 2009-06-25 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 融合へテロ二環式キナーゼ阻害剤 |
| WO2007085540A1 (en) | 2006-01-27 | 2007-08-02 | Glaxo Group Limited | 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives |
| JP5291616B2 (ja) | 2006-04-26 | 2013-09-18 | ジェネンテック， インコーポレイテッド | ホスホイノシチド３−キナーゼ抑制剤化合物およびその使用方法 |
| BRPI0710866A2 (pt) | 2006-04-26 | 2012-08-14 | Hoffmann La Roche | compostos farmacÊuticos |
| EP2050734A1 (en) | 2006-07-13 | 2009-04-22 | Kyowa Hakko Kirin Co., Ltd. | Pentadienamide derivative |
| CA2662580C (en) | 2006-09-11 | 2013-05-21 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| EP2049483A2 (en) | 2006-10-28 | 2009-04-22 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| EP2089415A1 (en) | 2006-11-22 | 2009-08-19 | Karus Therapeutics Limited | Depsipeptides and their therapeutic use |
| CN101663276A (zh) | 2007-01-31 | 2010-03-03 | 沃泰克斯药物股份有限公司 | 用作激酶抑制剂的2-氨基吡啶衍生物 |
| AU2008210455A1 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as kinase inhibitors |
| US8318781B2 (en) | 2007-04-26 | 2012-11-27 | Japan Science And Technology Agency | G-protein-conjugated receptor agonist |
| WO2008137270A1 (en) * | 2007-05-04 | 2008-11-13 | H. Lundbeck A/S | Methods of diagnosing and monitoring of npy y5 based disorders |
| EP2154965A4 (en) | 2007-05-29 | 2011-08-17 | Glaxosmithkline Llc | NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| WO2009063240A1 (en) | 2007-11-16 | 2009-05-22 | Arrow Therapeutics Limited | 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase |
| US20110288070A1 (en) | 2008-05-05 | 2011-11-24 | ROGERS Kathryn | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| WO2010015520A1 (de) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Substituierte naphthyridine und ihre verwendung als arzneimittel |
| CA2742550A1 (en) | 2008-10-03 | 2010-04-08 | Merck Serono S.A. | 4-morpholino-pyrido[3,2-d]pyrimidines |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| CN105669540A (zh) | 2009-01-28 | 2016-06-15 | 卡鲁斯治疗有限公司 | Scriptaid电子等排体及其在治疗中的用途 |
| AU2010286168B2 (en) | 2009-08-20 | 2014-05-15 | Karus Therapeutics Limited | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| ES2647368T3 (es) | 2010-10-08 | 2017-12-21 | Vib Vzw | Inhibidores de HDAC para tratar la enfermedad de Charcot-Marie-Tooth |
| AU2011343712B2 (en) | 2010-12-16 | 2015-09-17 | Genentech, Inc. | Tricyclic PI3k inhibitor compounds and methods of use |
| US9249087B2 (en) | 2011-02-01 | 2016-02-02 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
| EP2508510A1 (en) | 2011-04-06 | 2012-10-10 | Ikerchem, S.L. | Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof |
| CA2850757A1 (en) | 2011-10-03 | 2013-04-11 | The Trustees Of Columbia University In The City Of New York | Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1 |
| HK1200361A1 (en) * | 2011-10-04 | 2015-08-07 | 肝炎和病毒研究所 | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication |
| JP6117235B2 (ja) | 2011-12-15 | 2017-04-19 | ノバルティス アーゲー | Ｐｉ３ｋの活性または機能の阻害剤の使用 |
| KR101415742B1 (ko) | 2011-12-21 | 2014-07-04 | 영남대학교 산학협력단 | 6―아미노피리딘―3―올 유도체 또는 이의 약제학적 허용가능한 염 및 이를 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 약학조성물 |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| US9695108B2 (en) | 2012-08-23 | 2017-07-04 | Georgetown University | Compounds and methods of use thereof for treating tumors |
| IN2015DN03235A (online.php) | 2012-11-07 | 2015-10-02 | Karus Therapeutics Ltd | |
| WO2014072937A1 (en) | 2012-11-08 | 2014-05-15 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
| US20160052926A1 (en) | 2013-03-15 | 2016-02-25 | Hutchison Medipharma Limited | Novel pyrimidine and pyridine compounds and usage thereof |
| WO2014153280A1 (en) | 2013-03-22 | 2014-09-25 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| ES2688815T3 (es) | 2013-05-10 | 2018-11-07 | Karus Therapeutics Limited | Inhibidores de histona desacetilasa novedosos |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| WO2016031815A1 (ja) | 2014-08-26 | 2016-03-03 | 武田薬品工業株式会社 | 複素環化合物 |
| GB201419228D0 (en) * | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419264D0 (en) * | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
-
2013
- 2013-11-06 IN IN3235DEN2015 patent/IN2015DN03235A/en unknown
- 2013-11-06 CA CA2888861A patent/CA2888861A1/en not_active Abandoned
- 2013-11-06 WO PCT/GB2013/052917 patent/WO2014072714A1/en not_active Ceased
- 2013-11-06 AU AU2013343291A patent/AU2013343291B2/en not_active Ceased
- 2013-11-06 MX MX2015005132A patent/MX364295B/es active IP Right Grant
- 2013-11-06 ES ES13792060.9T patent/ES2672701T3/es active Active
- 2013-11-06 NZ NZ707366A patent/NZ707366A/en not_active IP Right Cessation
- 2013-11-06 US US14/441,401 patent/US9676765B2/en not_active Expired - Fee Related
- 2013-11-06 EP EP13792060.9A patent/EP2917202B1/en not_active Not-in-force
- 2013-11-06 JP JP2015540220A patent/JP6329958B2/ja not_active Expired - Fee Related
- 2013-11-06 CN CN201380058397.3A patent/CN104797573A/zh active Pending
-
2017
- 2017-05-08 US US15/589,491 patent/US10150763B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014072714A1 (en) | 2014-05-15 |
| CA2888861A1 (en) | 2014-05-15 |
| US10150763B2 (en) | 2018-12-11 |
| MX2015005132A (es) | 2015-12-07 |
| US9676765B2 (en) | 2017-06-13 |
| NZ707366A (en) | 2018-11-30 |
| JP6329958B2 (ja) | 2018-05-23 |
| IN2015DN03235A (online.php) | 2015-10-02 |
| EP2917202A1 (en) | 2015-09-16 |
| MX364295B (es) | 2019-04-22 |
| JP2015535273A (ja) | 2015-12-10 |
| US20150361074A1 (en) | 2015-12-17 |
| AU2013343291B2 (en) | 2018-05-10 |
| EP2917202B1 (en) | 2018-05-02 |
| US20180086750A1 (en) | 2018-03-29 |
| AU2013343291A1 (en) | 2015-05-07 |
| CN104797573A (zh) | 2015-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2688815T3 (es) | Inhibidores de histona desacetilasa novedosos | |
| US10150763B2 (en) | Histone deacetylase inhibitors and their use in therapy | |
| CA2995991A1 (en) | Compositions comprising a pi3k inhibitor and an hdac inhibitor | |
| US10533003B2 (en) | Polyheteroarl histone deacetylase inhibitors and their use in therapy | |
| AU2015340305B2 (en) | Diheteroaryl histone deacetylase inhibitors and their use in therapy | |
| HK1222660B (en) | Novel histone deacetylase inhibitors |